Detalhe da pesquisa
1.
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Cancer Immunol Immunother
; 71(4): 979-987, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34467417
2.
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
Cancer Immunol Immunother
; 69(5): 813-824, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32055920
3.
The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Cancer Immunol Immunother
; 66(4): 461-473, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011996
4.
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.
Haematologica
; 103(10): e458-e461, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748439
5.
Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells.
Haematologica
; 102(7): e257-e260, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28360148
6.
Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
Sci Rep
; 11(1): 12926, 2021 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34155276